atogepant : A secondary carboxamide resulting from the formal condensation of the carboxy group of (3'S)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic acid with the amino group of (3S,5S,6R)-3-amino-6-methyl-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-2-one. It is a selective oral, small-molecule antagonist of calcitonin gene-related peptide (CGRP) receptor that has been approved for the treatment of migraine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 72163100 |
| CHEMBL ID | 3991065 |
| CHEBI ID | 196955 |
| SCHEMBL ID | 4570348 |
| Synonym |
|---|
| atogepantum |
| (3's)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide |
| 1374248-81-3 |
| mk-8031 |
| CHEBI:196955 |
| atogepant |
| agn-241689 |
| qulipta |
| SCHEMBL4570348 |
| unii-7crv8rr151 |
| atogepant [usan:inn:who-dd] |
| atogepant [usan:inn] |
| (3's)-1',2',5,7-tetrahydro-n-((3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxospiro(6h-cyclopenta(b)pyridine-6,3'-(3h)pyrrolo(2,3-b)pyridine)-3-carboxamide |
| atogepant [usan] |
| atogepant [inn] |
| spiro(6h-cyclopenta(b)pyridine-6,3'-(3h)pyrrolo(2,3-b)pyridine)-3-carboxamide, 1',2',5,7-tetrahydro-n-((3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxo-, (3's)- |
| atogepant [who-dd] |
| atogepant [orange book] |
| 7CRV8RR151 , |
| HY-109022 |
| (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide |
| gtpl9730 |
| example 4 [us20120122911] |
| mk 8031; mk8031; atogepant |
| BCP29018 |
| CHEMBL3991065 |
| atogepant (usan) |
| D11313 |
| MS-30639 |
| EX-A6847 |
| us9833448, example 4 |
| us10272077, example 4 |
| bdbm362044 |
| qivuclwgaraqio-olixtkcusa-n |
| DTXSID901337079 |
| CS-0030524 |
| example 4 (us20120122911) |
| AKOS040747866 |
Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Atogepant has shown good efficacy and safety in the prophylactic treatment of migraine, and further studies are expected." | ( The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. Dai, Q; Meng, J; Tao, X; Wang, W; Wang, Z; Yan, Z; Zhou, Q, 2022) | 2.46 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Atogepant demonstrated treatment benefits as early as the first full day after treatment initiation, and sustained efficacy across each 4-week interval during the 12-week treatment period." | ( Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Ailani, J; Dabruzzo, B; Finnegan, M; Guo, H; Lipton, RB; Lu, K; Miceli, R; Schwedt, TJ; Severt, L; Silberstein, SD; Tassorelli, C; Trugman, JM, 2022) | 2.46 |
The combination use of atogepant and ubrogepants was safe and well tolerated in adult participants with a history of migraine enrolled in the study. These results are consistent with ato gepant's known safety profile and support long-term use.
Atogepant was rapidly absorbed (median time to maximum plasma concentration, ∼2 hours) with an apparent terminal elimination half-life of ∼11 hours. This open-label, single-center, 2-cohort, phase 1 trial evaluated the potential pharmacokinetic (PK) 2-way drug-drug interactions (DDIs)
| Excerpt | Reference | Relevance |
|---|---|---|
| " Atogepant was rapidly absorbed (median time to maximum plasma concentration, ∼2 hours) with an apparent terminal elimination half-life of ∼11 hours." | ( Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial. Boinpally, R; Borbridge, L; Butler, M; Jakate, A; Periclou, A, 2021) | 1.79 |
| " This open-label, single-center, 2-cohort, phase 1 trial evaluated the potential pharmacokinetic (PK) 2-way drug-drug interactions (DDIs), safety, and tolerability of atogepant and topiramate in healthy adults." | ( Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study. Boinpally, R; Borbridge, L; McGeeney, D; Trugman, J, 2023) | 1.36 |
The results of this study show that there are no clinically important changes in how atogepant is processed by the body when administered with esomeprazole. They can be safely taken together.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Male and female hRAMP1 mice were dosed with compound or vehicle and challenged with a charcoal meal suspension via oral gavage." | ( Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists. Heinz, BA; Huang, X; Johnson, KW; Li, B; Li, X; Yu, J, 2022) | 0.72 |
| "These results are consistent with atogepant's known safety profile and support long-term use of atogepant 60 mg once daily dosing as safe and well tolerated." | ( Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Diamond, M; Finnegan, M; Guo, H; Klein, BC; Marmura, MJ; McAllister, P; McVige, J; Mechtler, L; Miceli, R; Severt, L; Trugman, JM, 2023) | 1.47 |
| Role | Description |
|---|---|
| calcitonin gene-related peptide receptor antagonist | An antagonist at any calcitonin gene-related peptide receptor. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
| azaspiro compound | An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle. |
| organic heterotetracyclic compound | |
| trifluorobenzene | Any member of the class of fluorobenzenes carrying three fluorine substituents at unspecified positions. |
| piperidones | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Receptor activity-modifying protein 1 | Homo sapiens (human) | Ki | 0.0000 | 0.0000 | 0.0003 | 0.0008 | AID1657091 |
| Calcitonin gene-related peptide type 1 receptor | Homo sapiens (human) | Ki | 0.0000 | 0.0000 | 0.0282 | 0.5900 | AID1657091 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1657092 | Half life in human | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. |
| AID1657091 | Antagonist activity at human CLR/RAMP1 | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 40 (100.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (71.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 15 (37.50%) | 5.53% |
| Reviews | 11 (27.50%) | 6.00% |
| Case Studies | 1 (2.50%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (32.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||